Granados AMI

Language: Spanish
References: 7
Page: 73-74
PDF size: 89.68 Kb.

REFERENCES

1. Schwab N, Schneider-Hohendorf T, Melzer N, Cutter G, Wiendl H. Natalizumab-associated PML: Challenges with incidence, resulting risk, and risk stratification. Neurology. 2017; 88 (12): 1197-1205.

2. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006; 354 (9): 899-910.

3. Wattjes MP, Ciccarelli O, Reich DS, Banwell B, de Stefano N, Enzinger C, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 2021; 20 (8): 653-670.

4. Lee DH, Linker RA, Gold R. Spotlight on fumarates. Int MS J. 2008; 15 (1): 12-18.

5. Campbell N, Cohen J, Wiendl H, Foley J, Butzkueven H, Ryerson LZ, et al. Evaluating the efficacy and safety of 6 –week extended interval dosing of natalizumab via a prospective, controlled, randomized, open –label, rater-blinded phase 3b study. Neurology. 2019; 92: P3.2-095.

6. He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020; 19 (4): 307-316.

7. Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Maurer M, et al. Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Ther Adv Neurol Disord. 2021; 14: 17562864211039648.